Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study

Pulmonary Pharmacology & Therapeutics
Corrado PelaiaGirolamo Pelaia

Abstract

Mepolizumab is a humanized monoclonal antibody which targets interleukin-5 (IL-5) and is nowadays available in many countries for add-on biological therapy of severe eosinophilic asthma. Although the approval of mepolizumab use in clinical practice has been made possible by several successful pre-marketing controlled trials, so far only a very few studies have been performed in a real-life setting. Within such a context, our present observational investigation refers to 14 patients with refractory eosinophilic asthma, currently treated with mepolizumab at the Respiratory Unit of "Magna Græcia" University Hospital located in Catanzaro, Italy, whose anti-IL-5 treatment began between June 2017 and January 2018. These patients experienced a significant increase in asthma control test (ACT) score, that was evaluated at baseline (13.64 ± 3.00), as well as after 4 weeks (18.86 ± 3.15; p < 0.0001) and 24 weeks (20.07 ± 1.94; p < 0.0001) of add-on therapy with mepolizumab. This relevant improvement in symptom control was paralleled by a dramatic fall of blood eosinophil numbers, counted at baseline (647.1 ± 274.7 cells/μl), and at the 4th (147.8 ± 66.5 cells/μl; p < 0.0001) and 24th week (98.6 ± 40.3 cells/μl; p < 0.0001) after starting...Continue Reading

Citations

Oct 9, 2019·Expert Review of Respiratory Medicine·Marco CaminatiGianenrico Senna
Jun 13, 2020·Expert Opinion on Biological Therapy·Garry M Walsh
Aug 8, 2019·Expert Review of Clinical Immunology·Enrico HefflerGiorgio Walter Canonica
Jan 11, 2020·Frontiers in Physiology·Corrado PelaiaEnrico Heffler
Apr 23, 2019·Expert Opinion on Biological Therapy·Jaymin B MorjariaMassimo Caruso
Nov 7, 2019·Current Opinion in Allergy and Clinical Immunology·Diego BagnascoGiovanni Passalacqua
Jun 3, 2020·Therapeutic Advances in Respiratory Disease·Giovanna Elisiana CarpagnanoMaria Pia Foschino Barbaro
May 30, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Clairelyne DupinCamille Taillé
Aug 20, 2019·Expert Review of Clinical Immunology·Carlo CavaliereCristoforo Incorvaia
Mar 7, 2020·The European Respiratory Journal·Erin S HarveyPeter G Gibson
Apr 30, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Corrado PelaiaNunzio Crimi
Aug 21, 2020·The European Respiratory Journal·Tim HarrisonMelissa K Van Dyke
Nov 9, 2018·Current Opinion in Allergy and Clinical Immunology·Enrico HefflerGiorgio W Canonica
Dec 3, 2020·Respiratory Medicine·Anne Sofie BjerrumJohannes Martin Schmid
Nov 5, 2019·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Corrado PelaiaGirolamo Pelaia
Nov 19, 2020·Journal of Asthma and Allergy·Nora DrickHendrik Suhling
Dec 18, 2020·Frontiers in Immunology·Corrado PelaiaGirolamo Pelaia
Jun 28, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Corrado PelaiaGirolamo Pelaia
Sep 6, 2021·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Farrukh AbbasSandhya Khurana
Dec 25, 2021·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Elliot IsraelRafael Alfonso-Cristancho

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.